Inibidores de SGLT2 e Reduo de Riscos Cardacos: O estudo EMPA-REG OUTCOME mostrou que a empagliflozina, um inibidor de SGLT2, alcanou uma reduo de 14% no risco do desfecho composto primrio e uma reduo de 35% no risco de hospitalizao por insuficincia cardaca Fonte: ANAD
Potential side effects include hypoglycemia (low blood sugar), joint discomfort, water retention, and jaw/facial changes with prolonged use
For each included study, data was extracted on study design, baseline population characteristics, intervention details (type and dose of GLP-1 receptor agonists), comparator, mean follow-up duration and reported cardiovascular outcomes
doi: 10.1185/03007995.2010.549466 166 HamiltonAPattersonSPorterDGaultVAHolscherC
Facchinetti F, Espinola MSB, Dewailly D, et al
According to the warning, dulaglutide (the active ingredient in Trulicity) was found to cause an increased risk of thyroid C-cell tumors in male and female rates